Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia

A pilot study

J. H. Kersey, N. K.C. Ramsay, T. Kim, P. McGlave, W. Krivit, S. Levitt, A. Filipovich, W. Woods, M. O'Leary, Peter Felix Coccia, M. E. Nesbit

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The objective of the current study, initiated in 1976, was to improve the high relapse rate and subsequent mortality in children and yound adults with acute nonlymphocytic leukemia (ANLL). Seventeen patients, ages 6-28, with ANLL in first bone marrow remission, received cyclophosphamide and total body irradiation using a radiation scheme of 750 rad (7.5 Gy) total dose, delivered at a dose rate of 26 rad (26 cGy) per minute. Allogeneic marrow from HLA-matched sibling donors was followed by prophylactic therapy for graft-versus-host disease (GVHD). Median follow-up of the entire group is 20+ mo; survivors have been followed for a minimum of 14+ mo. Interstitial pneumonitis was observed in 6% of patients, and GVHD was observed in 29%. Seventy percent of patients are alive and in complete continuous remission. Two patients have relapsed (at 7 and 24 mo). Actuarial relapse-free survival is 76% at 1 yr and 64% at 5 yr. Quality of life in the disease-free survivors is excellent; all patients are free of active GVHD, receive no maintenance chemotherapy, and have high Karnofsky performance scores. High dose rate total body irradiation plus cyclophosphamide followed by allogeneic BMT may provide an opportunity for long-term complication-free survival in a substantial proportion of children and young adults with ANLL.

Original languageEnglish (US)
Pages (from-to)400-403
Number of pages4
JournalBlood
Volume60
Issue number2
StatePublished - Oct 25 1982

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Acute Myeloid Leukemia
Bone
Grafts
Graft vs Host Disease
Cyclophosphamide
Whole-Body Irradiation
Irradiation
Survivors
Bone Marrow
Chemotherapy
Maintenance Chemotherapy
Recurrence
Child Mortality
Survival
Dosimetry
Interstitial Lung Diseases
Siblings
Young Adult

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Kersey, J. H., Ramsay, N. K. C., Kim, T., McGlave, P., Krivit, W., Levitt, S., ... Nesbit, M. E. (1982). Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia: A pilot study. Blood, 60(2), 400-403.

Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia : A pilot study. / Kersey, J. H.; Ramsay, N. K.C.; Kim, T.; McGlave, P.; Krivit, W.; Levitt, S.; Filipovich, A.; Woods, W.; O'Leary, M.; Coccia, Peter Felix; Nesbit, M. E.

In: Blood, Vol. 60, No. 2, 25.10.1982, p. 400-403.

Research output: Contribution to journalArticle

Kersey, JH, Ramsay, NKC, Kim, T, McGlave, P, Krivit, W, Levitt, S, Filipovich, A, Woods, W, O'Leary, M, Coccia, PF & Nesbit, ME 1982, 'Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia: A pilot study', Blood, vol. 60, no. 2, pp. 400-403.
Kersey JH, Ramsay NKC, Kim T, McGlave P, Krivit W, Levitt S et al. Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia: A pilot study. Blood. 1982 Oct 25;60(2):400-403.
Kersey, J. H. ; Ramsay, N. K.C. ; Kim, T. ; McGlave, P. ; Krivit, W. ; Levitt, S. ; Filipovich, A. ; Woods, W. ; O'Leary, M. ; Coccia, Peter Felix ; Nesbit, M. E. / Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia : A pilot study. In: Blood. 1982 ; Vol. 60, No. 2. pp. 400-403.
@article{ad8c4860fc0f4e7e871376d08b9a5a24,
title = "Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia: A pilot study",
abstract = "The objective of the current study, initiated in 1976, was to improve the high relapse rate and subsequent mortality in children and yound adults with acute nonlymphocytic leukemia (ANLL). Seventeen patients, ages 6-28, with ANLL in first bone marrow remission, received cyclophosphamide and total body irradiation using a radiation scheme of 750 rad (7.5 Gy) total dose, delivered at a dose rate of 26 rad (26 cGy) per minute. Allogeneic marrow from HLA-matched sibling donors was followed by prophylactic therapy for graft-versus-host disease (GVHD). Median follow-up of the entire group is 20+ mo; survivors have been followed for a minimum of 14+ mo. Interstitial pneumonitis was observed in 6{\%} of patients, and GVHD was observed in 29{\%}. Seventy percent of patients are alive and in complete continuous remission. Two patients have relapsed (at 7 and 24 mo). Actuarial relapse-free survival is 76{\%} at 1 yr and 64{\%} at 5 yr. Quality of life in the disease-free survivors is excellent; all patients are free of active GVHD, receive no maintenance chemotherapy, and have high Karnofsky performance scores. High dose rate total body irradiation plus cyclophosphamide followed by allogeneic BMT may provide an opportunity for long-term complication-free survival in a substantial proportion of children and young adults with ANLL.",
author = "Kersey, {J. H.} and Ramsay, {N. K.C.} and T. Kim and P. McGlave and W. Krivit and S. Levitt and A. Filipovich and W. Woods and M. O'Leary and Coccia, {Peter Felix} and Nesbit, {M. E.}",
year = "1982",
month = "10",
day = "25",
language = "English (US)",
volume = "60",
pages = "400--403",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia

T2 - A pilot study

AU - Kersey, J. H.

AU - Ramsay, N. K.C.

AU - Kim, T.

AU - McGlave, P.

AU - Krivit, W.

AU - Levitt, S.

AU - Filipovich, A.

AU - Woods, W.

AU - O'Leary, M.

AU - Coccia, Peter Felix

AU - Nesbit, M. E.

PY - 1982/10/25

Y1 - 1982/10/25

N2 - The objective of the current study, initiated in 1976, was to improve the high relapse rate and subsequent mortality in children and yound adults with acute nonlymphocytic leukemia (ANLL). Seventeen patients, ages 6-28, with ANLL in first bone marrow remission, received cyclophosphamide and total body irradiation using a radiation scheme of 750 rad (7.5 Gy) total dose, delivered at a dose rate of 26 rad (26 cGy) per minute. Allogeneic marrow from HLA-matched sibling donors was followed by prophylactic therapy for graft-versus-host disease (GVHD). Median follow-up of the entire group is 20+ mo; survivors have been followed for a minimum of 14+ mo. Interstitial pneumonitis was observed in 6% of patients, and GVHD was observed in 29%. Seventy percent of patients are alive and in complete continuous remission. Two patients have relapsed (at 7 and 24 mo). Actuarial relapse-free survival is 76% at 1 yr and 64% at 5 yr. Quality of life in the disease-free survivors is excellent; all patients are free of active GVHD, receive no maintenance chemotherapy, and have high Karnofsky performance scores. High dose rate total body irradiation plus cyclophosphamide followed by allogeneic BMT may provide an opportunity for long-term complication-free survival in a substantial proportion of children and young adults with ANLL.

AB - The objective of the current study, initiated in 1976, was to improve the high relapse rate and subsequent mortality in children and yound adults with acute nonlymphocytic leukemia (ANLL). Seventeen patients, ages 6-28, with ANLL in first bone marrow remission, received cyclophosphamide and total body irradiation using a radiation scheme of 750 rad (7.5 Gy) total dose, delivered at a dose rate of 26 rad (26 cGy) per minute. Allogeneic marrow from HLA-matched sibling donors was followed by prophylactic therapy for graft-versus-host disease (GVHD). Median follow-up of the entire group is 20+ mo; survivors have been followed for a minimum of 14+ mo. Interstitial pneumonitis was observed in 6% of patients, and GVHD was observed in 29%. Seventy percent of patients are alive and in complete continuous remission. Two patients have relapsed (at 7 and 24 mo). Actuarial relapse-free survival is 76% at 1 yr and 64% at 5 yr. Quality of life in the disease-free survivors is excellent; all patients are free of active GVHD, receive no maintenance chemotherapy, and have high Karnofsky performance scores. High dose rate total body irradiation plus cyclophosphamide followed by allogeneic BMT may provide an opportunity for long-term complication-free survival in a substantial proportion of children and young adults with ANLL.

UR - http://www.scopus.com/inward/record.url?scp=0019963931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019963931&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 400

EP - 403

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -